Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. 1995

W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
Department of Nuclear Medicine, National Cheng Kung University Hospital Tainan, Taiwan, Republic of China.

Tissue polypeptide specific antigen (TPS) is the M3 epitope of the tissue polypeptide antigen, and a specific epithelial proliferation marker. To examine the benefit of urine TPS (UTPS) measurement in the diagnosis and classification of biological properties of transitional cell carcinoma (TCC), a radioimmunoassay of U-TPS was measured in patients with active TCC (n = 56), at tumor-free status (n = 36), with inflammatory urological disease (n = 44), and age-sex adjusted normal subjects (n = 75). Both neoplastic and inflammatory urological diseases had an increase in U-TPS levels (U/gm creatinine) compared to normal individuals (p = 0.0005), while it normalized in tumor-free condition (p = 0.007). For patients with active TCC, a strong positive association was observed between U-TPS values and both histological grading (p = 0.05) and positive cytology (p = 0.05). U-TPS levels were significantly higher in the presence of nodal or systemic metastasis (p = 0.008 by ANOVA test). Measurement of U-TPS appeared to be an indicator of poor outcome for patients with bladder cancer (p = 0.05 by t test) for a mean follow-up of 26 months. The results indicate that determination of U-TPS can be a supplement in assessing the biological properties of TCC, and may be helpful in identifying patients who need meticulous peri-operative staging survey.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females

Related Publications

W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 1997, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 2006, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 1994, Clinica chimica acta; international journal of clinical chemistry,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 1997, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 1994, European journal of cancer (Oxford, England : 1990),
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 2000, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 2000, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 2004, Voprosy onkologii,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
January 2002, Anticancer research,
W J Yao, and C J Chang, and S H Chan, and N H Chow, and H L Cheng, and T S Tzai, and S N Lin
October 1998, Wiener klinische Wochenschrift,
Copied contents to your clipboard!